Physician profile
Labony Mookerjee
NPI 1285840637
$695.62
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $96.01 · 2022: $11.92 · 2023: $206 · 2024: $14.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $220.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $214.10 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $172.67 | 2019-2023 | Vaxneuvance, Rotateq, Gardasil 9 |
| Pfizer INC. | $89.42 | 2019-2023 | |
| Gilead Sciences, INC. | $54.74 | 2019-2020 | |
| Glaxosmithkline, LLC. | $49.63 | 2019-2024 | Arexvy, Shingrix |
| Shire North American Group INC | $30.00 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.32 | 2023 | Rexulti |
| Tris Pharma INC | $15.73 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.30 | 2019 | |
| Lilly USA, LLC | $12.01 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.89 | 2020 | |
| Neos Therapeutics, LP | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Labony Mookerjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.